Mirum Pharmaceuticals, Inc. Common Stock (MIRM) Stock Price
MIRMStock
$80.14+7.69%52W
Market Cap$5.20B
P/E—
PEG Ratio—
Div yield—
Beta0.76
MIRM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-27.20%
Price vs S&P 500 (4W)-11.57%
VGM Score48.16
MIRM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.75 | -$0.80 | -7.44%(-$0.06) | |
| Q1 2026 | -$0.35 | -$1.08 | -205.63%(-$0.73) | |
| Q4 2025 | $0.06 | -$0.12 | -308.70%(-$0.18) | |
| Q3 2025 | -$0.16 | $0.05 | +131.53%(+$0.21) | |
| Q2 2025 | -$0.33 | -$0.12 | +64.05%(+$0.21) |
MIRM Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.32
4.35
4.35
4.35
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
MIRMMirum Pharmaceuticals, Inc. Common Stock | F | B | C | 8.4x | 44.0% | 81.7% | — | $80.14 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Mirum Pharmaceuticals, Inc. Common Stock
Mirum Pharmaceuticals is a biopharmaceutical company developing therapies for rare and orphan liver diseases. The company markets Livmarli, an FDA-approved bile acid transporter inhibitor for cholestatic pruritus in Alagille syndrome patients. Mirum's pipeline includes maralixibat for pediatric cholestatic liver diseases and volixibat for adult patients with cholestatic conditions.